TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search

SGIOY

Shionogi & Co Ltd ADR

PINKCommon Stock
$8.65
+0.23%today

No SEC filings for this security

Shionogi & Co Ltd ADR is a foreign or OTC-listed security (PINK) that doesn't file with the SEC, so the grounded research view — financials, filings, insider activity and the call — isn't available. Price and news only.

Key stats

52-week range$7.75 – $11.48
7.7552-week11.48
Market cap
$14.7B
Volume
45.1K
1Y return
+2.74%
Beta
0.04

Price · 1Y

$8.65▲ +2.74%
over 1Y
L $7.75H $11.48

Recent news

market news →
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common WartsBullish
finance.yahoo.com· 2026-06-22
Shionogi (TSE:4507) Valuation Check As XOCOVA Wins First US FDA Approval For COVID 19 Post Exposure ProphylaxisBullish
finance.yahoo.com· 2026-06-10
New Polymorph of Indomethacin DiscoveredBullish
finance.yahoo.com· 2026-06-09
Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following ExposureBullish
finance.yahoo.com· 2026-06-01
PrEP Wisdom: ViiV Healthcare Launches New Campaign to Support Informed HIV Prevention ChoicesBullish
finance.yahoo.com· 2026-06-01
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following ExposureBullish
finance.yahoo.com· 2026-05-13
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue EstimatesBullish
finance.yahoo.com· 2026-05-07
D-Wave CEO on quantum computing's ChatGPT moment, Nvidia, & moreBullish
finance.yahoo.com· 2026-04-14

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.